Advertising and personal-information laws and regulations
First written in FY2022. 4 of 7 entries say "Materialised", first in FY2024-Q1. Latest entry: FY2025.
Eyez moved to the "Worse" side of this theme in 2024, 1 year before the typical company in this theme (2025).
The whole theme swung hardest in 2025: 6 of 29 companies on the "Worse" side.
50 other companies' latest entry also says "Restated".
- FY2025RestatedAnnual report
「Advertising-representation regulations, including the Designated Notice under the Act against Unjustifiable Premiums and Misleading Representations that took effect in October 2023, commonly known as the stealth-marketing regulation, have tended to become stricter year by year.」
The company continues to identify advertising regulations including the Pharmaceuticals and Medical Devices Act, Health Promotion Act and advertising-representation law as risks, and describes the strengthening of advertising-representation rules, including the stealth-marketing regulation effective October 2023. - FY2025-H1MaterialisedAnnual report
「However, partly because advertisers held back on placements due to stealth-marketing regulations, Trami revenue was ¥191 million, down 12.5% year on year.」
Advertiser restraint due to stealth-marketing regulations continued, and Trami revenue declined 12.5% year on year. The regulatory risk had a direct impact on interim performance. - FY2024MaterialisedAnnual report
「As a result, although we recovered from the impact of advertisers holding back on placements due to stealth-marketing regulations, Trami revenue was ¥408 million, down 4.2% from the previous fiscal year.」
Advertiser restraint due to stealth-marketing regulations continued to affect Trami, with revenue declining 4.2% from the previous fiscal year. - FY2024-H1MaterialisedAnnual report
「However, partly because advertisers held back on placements due to stealth-marketing regulations in the first quarter, Trami revenue for the interim accounting period was ¥219 million, down 4.5% year on year.」
Advertiser restraint due to stealth-marketing regulations continued to affect the interim accounting period, with Trami revenue declining 4.5% year on year. - FY2024-Q1MaterialisedAnnual report
「However, partly because advertisers held back on placements due to stealth-marketing regulations, Trami revenue was ¥101 million, down 21.3% year on year.」
Advertiser restraint due to stealth-marketing regulations actually occurred, and Trami revenue declined 21.3% year on year. - FY2023RestatedAnnual report
「We are subject to regulations including the Pharmaceuticals and Medical Devices Act, the Health Promotion Act, the Act on the Protection of Personal Information, the Act against Unjustifiable Premiums and Misleading Representations, the Copyright Act and the Trademark Act.」
The company continues to identify these regulations and restrictions on the business arising from violations or regulatory changes as risks. - FY2022First statedAnnual report
「We are subject to regulations including the Pharmaceuticals and Medical Devices Act, the Health Promotion Act, the Act on the Protection of Personal Information, the Act against Unjustifiable Premiums and Misleading Representations, the Copyright Act and the Trademark Act.」
The company identifies violations of or changes to the Pharmaceuticals and Medical Devices Act, Health Promotion Act, personal-information protection law, advertising-representation law, Copyright Act and Trademark Act as risks.